Evidence map›Paper›PMID 39250522›Full record

SynthesisPLoS neglected tropical diseases2024

Effects of Schistosoma haematobium infection and treatment on the systemic and mucosal immune phenotype, gene expression and microbiome: A systematic review.

Anna M Mertelsmann, Sheridan F Bowers, Drew Wright, Jane K Maganga, Humphrey D Mazigo, Lishomwa C Ndhlovu, John M Changalucha, Jennifer A Downs

Abstract readSystematic Review
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anna M MertelsmannDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, United States of America.ORCID 0000-0003-4448-0600
Sheridan F BowersCenter for Global Health, Weill Cornell Medicine, New York, New York, United States of America.
Drew WrightSamuel J. Wood Library & C.V. Starr Biomedical Information Center, Weill Cornell Medical College, New York, New York, United States of America.
Jane K MagangaMwanza Intervention Trials Unit/National Institute for Medical Research, Mwanza, Tanzania.
Humphrey D MazigoDepartment of Parasitology and Entomology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Lishomwa C NdhlovuDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, United States of America.
John M ChangaluchaMwanza Intervention Trials Unit/National Institute for Medical Research, Mwanza, Tanzania.
Jennifer A DownsCenter for Global Health, Weill Cornell Medicine, New York, New York, United States of America.

Funding

Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
T32: Pathogenesis of Infectious Diseases Training ProgramT32AI007613 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 1999 to 2026
$8.8M
Genital Immune, Mucosal, and Viral Effects of Female Genital Schistosomiasis in TanzaniaR01AI168306 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jennifer Alzos Downs · 2022 to 2026
$3.1M
Post-Doctoral Fellowship Training in HIV Clinical InvestigationD43TW011826 · FIC · WEILL MEDICAL COLL OF CORNELL UNIV · PI Daniel W Fitzgerald, Saidi Kapiga · 2021 to 2026
$1.9M
Schistosomiasis and Women's Reproductive HealthK24AI182638 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jennifer Alzos Downs · 2024 to 2026
$611k
FIC NIH HHS D43 TW011826NCATS NIH HHS UL1 TR002384NIAID NIH HHS K24 AI182638NIAID NIH HHS R01 AI168306NIAID NIH HHS T32 AI007613
6 · The paper itself

Abstract

backgroundUrogenital schistosomiasis caused by Schistosoma haematobium affects approximately 110 million people globally, with the majority of cases in low- and middle-income countries. Schistosome infections have been shown to impact the host immune system, gene expression, and microbiome composition. Studies have demonstrated variations in pathology between schistosome subspecies. In the case of S. haematobium, infection has been associated with HIV acquisition and bladder cancer. However, the underlying pathophysiology has been understudied compared to other schistosome species. This systematic review comprehensively investigates and assimilates the effects of S. haematobium infection on systemic and local host mucosal immunity, cellular gene expression and microbiome.

methodsWe conducted a systematic review assessing the reported effects of S. haematobium infections and anthelmintic treatment on the immune system, gene expression and microbiome in humans and animal models. This review followed PRISMA guidelines and was registered prospectively in PROSPERO (CRD42022372607). Randomized clinical trials, cohort, cross-sectional, case-control, experimental ex vivo, and animal studies were included. Two reviewers performed screening independently.

resultsWe screened 3,177 studies and included 94. S. haematobium was reported to lead to: (i) a mixed immune response with a predominant type 2 immune phenotype, increased T and B regulatory cells, and select pro-inflammatory cytokines; (ii) distinct molecular alterations that would compromise epithelial integrity, such as increased metalloproteinase expression, and promote immunological changes and cellular transformation, specifically upregulation of genes p53 and Bcl-2; and (iii) microbiome dysbiosis in the urinary, intestinal, and genital tracts.

conclusionS. haematobium induces distinct alterations in the host's immune system, molecular profile, and microbiome. This leads to a diverse range of inflammatory and anti-inflammatory responses and impaired integrity of the local mucosal epithelial barrier, elevating the risks of secondary infections. Further, S. haematobium promotes cellular transformation with oncogenic potential and disrupts the microbiome, further influencing the immune system and genetic makeup. Understanding the pathophysiology of these interactions can improve outcomes for the sequelae of this devastating parasitic infection.

Indexed as

Immunity, MucosalMicrobiotaSchistosoma haematobiumSchistosomiasis haematobiaAnimalsAnthelminticsGene ExpressionHumansPhenotypeAnthelmintics

Identifiers

PMID39250522
PMCPMC11412685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.